A Safety and Tolerability Study of RAD001 (mTOR Inhibitor) in Combination With Two Dosing Schedules of LBH589B (Histone Deacetylase Inhibitor) in Solid Tumors/ Lymphomas With Enrichment for EBV-Driven Tumors.

Trial Profile

A Safety and Tolerability Study of RAD001 (mTOR Inhibitor) in Combination With Two Dosing Schedules of LBH589B (Histone Deacetylase Inhibitor) in Solid Tumors/ Lymphomas With Enrichment for EBV-Driven Tumors.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Apr 2017

At a glance

  • Drugs Everolimus (Primary) ; Panobinostat (Primary)
  • Indications Gastric cancer; Lymphoma; Nasopharyngeal cancer; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 29 Mar 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2018.
    • 18 Aug 2015 Planned End Date changed from 1 Jun 2013 to 1 Dec 2016 as per ClinicalTrials.gov record.
    • 18 Aug 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top